Opinion|Videos|March 4, 2025
Third-Line Treatments and Current Practice Guidelines in Advanced RCC
Author(s)Pedro Barata, MD, MSc, FACP
A panelist discusses how, based on the NCCN guidelines for kidney cancer, third-line treatment options for this patient include cabozantinib, lenvatinib plus everolimus, tivozanib, and everolimus monotherapy. Clinical trials and best supportive care remain important considerations at this stage.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the third-line options for this patient per the NCCN guidelines for kidney cancer?
Advertisement
Related to this article
Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.
The FDA has approved Omcazio, a capsule-based formulation of cabozantinib as a laurylsulfate salt, that demonstrated bioequivalence to the existing tablet.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
A Look Inside CONVERGE: Intratumoral Therapy Comes to Locally Advanced NSCLC
2
DiBardino Outlines Phase 2 CONVERGE Trial Design of Radioenhancer in NSCLC
3
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
4
Taletrectinib Sustains Durable ROS1+ NSCLC Responses at 3-Year Follow-Up
5